Navigation Links
Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
Date:9/10/2007

ete

resolution of lung metastases by CT/PET with significant improvement in

dypsnea (shortness of breath);

-- 1 patient (11 prior regimens, 5 with trastuzumab, 2 with lapatinib)

showed 10% reduction in tumor mass with change consistent with tumor

necrosis and a decrease in 2 tumor markers (64% CEA, 63% CA27.29);

-- 1 patient (5 prior regimens) showed a partial response after 2 cycles,

confirmed after 4 cycles, with 52% decrease hepatic lesions);

-- 5 patients had extended stable disease (4, 6+, 6+, 8 and 10 months).

Of the 3 patients with ovarian cancer,

-- 1 patient (13 prior regimens) who was on study for more than 19 months

with evaluable disease had a near complete resolution of ascites and

left pleural effusion at the end of cycle 2, and an 83%

decrease in CA125.

Toxicities were mainly Grade 1 and 2 (diarrhea, fatigue, headache, arthralgia, nausea). One patient with multiple prior trastuzumab and doxorubicin containing regimens experienced a dose-limiting toxicity of shortness of breath and left ventricular ejection fraction reduction at 100 mg/m2. Two patients treated at 80 mg/m2 experienced reversible Grade 3 ocular keratitis; following a treatment holiday both patients continued therapy with reduced doses (one patient remains on study). Kosan plans to continue to enroll patients at the 80 mg/m2 for further safety and efficacy evaluation.

Expanded Phase 1 Trial Includes Paclitaxel

Kosan has expanded the Phase 1 trial to add weekly dosing with paclitaxel (Taxol (R)). In this triplet combination regimen, patients will continue to receive trastuzumab at full dose on a continuous weekly schedule. Alvespimycin will be dosed weekly for 3 weeks out of 4, and paclitaxel will be given on the same schedule.

Alvespimycin Development Plan

In the fourth quarter of 2007, Kosan plans to initiate a Phase 2 trial of alvespimycin as monotherapy
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
2. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
6. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
7. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
8. ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met Inhibitor, for Oral Presentation at ASCO
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Restore Health, a leading personalized medicine company ... it is now offering pharmacogenetics testing that provides ... upon their particular genetic makeup. Comprehensive medication management ... a patient,s genetics and their entire drug regimen.  ... this new service to healthcare providers and their ...
(Date:7/24/2014)... UNION CITY, Calif., July 24, 2014  Abaxis, Inc. ... manufacturing point-of-care blood analysis systems, today reported financial results ... First quarter overview: , Revenues of ... , Diluted EPS of $0.21, up 50% over ... , Medical market revenues of $7.2 million, up 20% ...
(Date:7/24/2014)... 2014 Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... to discuss the Company,s Second Quarter 2014 financial ... earnings conference call and webcastWhen: , July ... chairman, president and chief executive officer ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... , WASHINGTON, Dec. 10 BioWorld Today ... Research and Manufacturers of America ( PhRMA ) that identifies 97 new ... conditions. , The report , which was released ahead of ... found that the 97 products in development include 23 vaccines and 54 ...
... , MILFORD, Mass., Dec. 10 ... that it is partnering with the NC BioNetwork Pharmaceutical ... NC, to educate and train students and workers in ... biopharmaceutical industry. The Pharmaceutical Center, which is a collaborative ...
Cached Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4
(Date:7/27/2014)... Bags underneath the eyes is one condition ... there are a range of new products now available from ... baggy eyes serum review that is now posted for adults ... the issues with baggy eyes and how the natural ingredients ... The guide also provides a detailed overview of the creams ...
(Date:7/27/2014)... The report, “Glass Fiber & ... Raw Material, By Manufacturing Process, By Application (Transportation, ... Geography – Global Trends & Forecast to 2019”, ... with an analysis and forecast by value and ... 107 figures spread through 347 slides and in-depth ...
(Date:7/27/2014)... Prominent Vancouver Chiropractors, Dr. Shervin Ranjbar and ... hamstring release procedure in Vancouver, BC. Both these chiropractors ... and have years of experience in the field of ... by the two professionals using a foam roller exercise. ... release tight hamstrings and relieve the client of the ...
(Date:7/27/2014)... City (Sunday July 27 11:45 am ET): ... at the surgical sitehas been reduced by 77 ... in the American College of Surgeons National Surgical ... new case study presented at the 2014 ACS ... British Columbia, reportedly reduced its rate of cardiac ...
(Date:7/27/2014)... 2014 Metachromatic leukodystrophy (MLD, also ... disease which is commonly listed in the family ... as it affects the metabolism of sphingolipids. Leukodystrophies ... fatty covering which acts as an insulator around ... systems. MLD involves cerebroside sulfate accumulation. Metachromatic leukodystrophy, ...
Breaking Medicine News(10 mins):Health News:Baggy Eyes Serum Review Posted for Men and Women at Cherry News Website 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 4Health News:Renowned Vancouver Chiropractors Demonstrates Hamstring Release in Vancouver, BC 2Health News:Surgical safety program greatly reduces surgical site infections for heart operations 2Health News:Surgical safety program greatly reduces surgical site infections for heart operations 3Health News:Surgical safety program greatly reduces surgical site infections for heart operations 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5
... Hospital today became the first in Ontario to implant a small ... about the size of a Zippo lighter is the ... highest level of energy, 40 joules. The narrow shape ... incision in the patient,s chest, which should mean a faster recovery ...
... , TUESDAY, Dec. 21 (HealthDay News) -- Like ... their sex, say researchers who spent 14 years observing a ... researchers found that both male and female chimpanzee youngsters play ... treat the sticks as would mothers caring for their infants. ...
... , TUESDAY, Dec. 21 (HealthDay News) -- Children ... independent in adulthood, new study findings suggest. For example, ... shoes in the bedroom or apples in the supermarket, according ... Kingdom. The study authors asked 20 children with autism ...
... , HOUSTON, Dec. 21, 2010 The day when an ... painless pill instead of a toxic drug cocktail is the ... Houston (UH) scientist. Preethi Gunaratne, assistant professor in ... of tiny genetic molecules known as microRNAs and pinpointing those ...
... morbidly obese persons face many health issues -- heart disease, ... chances of dying while driving during a severe auto accident ... vehicle crash, a moderately obese driver faces a 21 percent ... 56 percent increased risk of not surviving, according to a ...
... By Jenifer Goodwin HealthDay Reporter , TUESDAY, ... discovered in recent years, losing a job is upsetting and ... But buck up. About a year later, the majority ... returned to their previous levels of happiness, a new study ...
Cached Medicine News:Health News:Young Female Chimps Use Sticks as 'Dolls' 2Health News:UH biochemist works to revolutionize ovarian cancer treatment 2Health News:UH biochemist works to revolutionize ovarian cancer treatment 3Health News:UH biochemist works to revolutionize ovarian cancer treatment 4Health News:Obesity increases risk of death in severe vehicle crashes, study shows 2Health News:Most People Regain Happiness After Job Loss 2Health News:Most People Regain Happiness After Job Loss 3
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
The Erythrocyte Sedimentation Rate (ESR) can be used as a nonspecific search technique in case of suspicion of inflammatory reactions as well as for judgement of their development. VACUETTE ESR tubes...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Glucose tubes contain an anti-coagulant and a stabiliser. The tubes are ideal for glucose and lactate determinations....
Medicine Products: